AbbVie (ABBV) Raises Quarterly Dividend 12.3% to $0.64; 4.2% Yield
- Stocks end near flat as investors assess earnings, data
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Taiwan Semi (TSM) Q1 profit beats expectations on AI demand
- Stocks have priced in much of the 2024 optimism - Wells Fargo
- Intuitive Surgiical (ISRG) beats earnings, revenue expectations in Q1
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Netflix (NFLX) Tops Q1 EPS by 77c, Offers Guidance
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
- After-hours movers: United Airlines, J.B. Hunt, and more
Credit Suisse Downgrades Abbvie (ABBV) to Neutral; Path to Upside Difficult
October 31, 2016 7:13 AM EDTCredit Suisse downgraded Abbvie (NYSE: ABBV) from Outperform to Neutral with a price target of $60.00 (from $70.00), saying while valuation may be compelling the path to upside is difficult.
Analyst Vamil Divan commented, "We downgrade ABBV shares to Neutral and lower our target price to $60 (from... More
AbbVie (ABBV) Tops Q3 EPS by 1c; Boosts FY16 EPS Outlook
October 28, 2016 7:44 AM EDTAbbVie (NYSE: ABBV) reported Q3 EPS of $1.21, $0.01 better than the analyst estimate of $1.20. Revenue for the quarter came in at $6.43 billion versus the consensus estimate of $6.56 billion.
Global HUMIRA sales increased 11.3 percent on a reported basis. Operational HUMIRA sales increased 12.1 percent, excluding a... More